Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1373 ARTÍCULOS , VIENDO DEL 286 AL 300

Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?

Aisen PS, Vellas B.

J Nutr Health Aging. 2013 Jan;17(1):49-50. doi: 10.1007/s12603-013-0001-3.

Coupled cognitive and functional change in Alzheimer's disease and the influence of depressive symptoms

Zahodne LB, Devanand DP, Stern Y.

J Alzheimers Dis. 2013;34(4):851-60. doi: 10.3233/JAD-121921.

Alzheimer's disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells

Wojda U, Kuznicki J.

J Alzheimers Dis. 2013;34(3):563-88. doi: 10.3233/JAD-121984.

Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms

Chin J, Scharfman HE.

Epilepsy Behav. 2013 Mar;26(3):343-51. doi: 10.1016/j.yebeh.2012.11.040. Epub 2013 Jan 13.

The neurodegeneration in Alzheimer disease and the prion protein

Forloni G, Sclip A, Borsello T, Balducci C.

Prion. 2013 Jan-Feb;7(1):60-5. doi: 10.4161/pri.23286. Epub 2013 Jan 1.

TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial

Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK.

Alzheimers Dement. 2013 Mar;9(2):132-6. doi: 10.1016/j.jalz.2012.10.009. Epub 2013 Jan 18.

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13. doi: 10.1097/WNF.0b013e318279bcfa.

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study

Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b.

Dementia in 2012: Further insights into Alzheimer disease pathogenesis

Weiner MW.

Nat Rev Neurol. 2013 Feb;9(2):65-6. doi: 10.1038/nrneurol.2012.275. Epub 2013 Jan 22.

The immunological basis of degenerative diseases of the eye

Nussenblatt RB, Liu B, Wei L, Sen HN.

Int Rev Immunol. 2013 Feb;32(1):97-112. doi: 10.3109/08830185.2012.740536.

Impaired transcription in Alzheimer's disease: key role in mitochondrial dysfunction and oxidative stress

Caldeira GL, Ferreira IL, Rego AC.

J Alzheimers Dis. 2013;34(1):115-31. doi: 10.3233/JAD-121444.

The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease

Sivak JM.

Invest Ophthalmol Vis Sci. 2013 Jan 30;54(1):871-80. doi: 10.1167/iovs.12-10827.

Pharmacogenomics in Alzheimer's disease: a genome-wide association study of response to cholinesterase inhibitors

Martinelli-Boneschi F, Giacalone G, Magnani G, Biella G, Coppi E, Santangelo R, Brambilla P, Esposito F, Lupoli S, Clerici F, Benussi L, Ghidoni R, Galimberti D, Squitti R, Confaloni A, Bruno G, Pichler S, Mayhaus M, Riemenschneider M, Mariani C, Comi G, Scarpini E, Binetti G, Forloni G, Franceschi M, Albani D.

Neurobiol Aging. 2013 Jun;34(6):1711.e7-13. doi: 10.1016/j.neurobiolaging.2012.12.008. Epub 2013 Jan 29.

Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 1: clinical and historical background

Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, Pawelec G.

Discov Med. 2013 Jan;15(80):23-32.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias